The biopharmaceutical company Sorrento Therapeutics reports positive trial results utilizing Sofusa Lymphatic Delivery of the biological medical product Etanercept after completing its first Phase 1b human proof of concept study. Sorrento Therapeutics use Obducat’s NIL technology when fabricating the nanotopography draped microneedles which are part of the Sofusa® Drug Delivery System.
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements in disease activity when switched to Sofusa lymphatic delivery.
The results were presented at the American College of Rheumatology (ACR) Convergence 2022 Conference on November 13, 2022 as an abstract and poster entitled “Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections”.
Preliminary results indicate that 100% of the patients (7 of 7) who have completed the first cohort of the study (12 weeks) achieved a significant improvement in their Rheumatoid Arthritis Disease Activity at 50% of the subcutaneous dose (25mg).
In a Sorrento Therapeutics press release Henry Ji, Ph.D., President and CEO of Sorrento stated; “We are very encouraged by these results, and appreciative of the ACR’s acceptance of our publication. The Sofusa platform is fulfilling the promise that we expected when we acquired this platform. The technology, combined with our proprietary G-MAB library and antibody manufacturing capabilities, gives us an engine for developing a pipeline of novel lymphatic therapies for autoimmune diseases, cancers, and infectious diseases.” He continued; “This also gives hope to the many patients who are not achieving an adequate response on current biologic therapies delivered by traditional injections and infusions.”
Read Sorrento’s full Press Release here: Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcuta – Sorrento Therapeutics
Read more about the Sofusa Lymphatic Delivery System by clicking below link:
Lymphatic Delivery System – Sorrento Therapeutics